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Background: Rapid mobilisation from industry and academia 
following the outbreak of the novel coronavirus, severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), led to the 
development and availability of SARS-CoV-2 lateral flow 
immunoassays (LFAs). High quality LFAs are urgently needed at the 
point of care to add to currently available diagnostic tools. In this 
study, we provide evaluation data for ten LFAs suitable for use at the 
point of care. 
Methods: COVID-19 positive patients (N=45), confirmed by reverse 
transcription – quantitative polymerase chain reaction (RT-qPCR), were 
recruited through the International Severe Acute Respiratory and 
Emerging Infection Consortium - Coronavirus Clinical Characterisation 
Consortium (ISARIC4C) study. Sera collected from patients with 
influenza A (N=20), tuberculosis (N=5), individuals with previous 
flavivirus exposure (N=21), and healthy sera (N=4), collected pre-
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pandemic, were used as negative controls. Ten LFAs manufactured or 
distributed by ASBT Holdings Ltd, Cellex, Fortress Diagnostics, 
Nantong Egens Biotechnology, Mologic, NG Biotech, Nal von Minden 
and Suzhou Herui BioMed Co. were evaluated. 
Results: Compared to RT-qPCR, sensitivity of LFAs ranged from 87.0-
95.7%. Specificity against pre-pandemic controls ranged between 
92.0-100%. Compared to IgG ELISA, sensitivity and specificity ranged 
between 90.5-100% and 93.2-100%, respectively. Percentage 
agreement between LFAs and IgG ELISA ranged from 89.6-92.7%. 
Inter-test agreement between LFAs and IgG ELISA ranged between 
kappa=0.792-0.854. 
Conclusions: LFAs may serve as a useful tool for rapid confirmation of 
ongoing or previous infection in conjunction with clinical suspicion of 
COVID-19 in patients attending hospital. Impartial validation prior to 
commercial sale provides users with data that can inform best use 
settings.
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Introduction
In December 2019, an outbreak of severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China 
before spreading globally, with the World Health Organization 
(WHO) declaring its pandemic status in March 20201. The 
reference standard for diagnosis of SARS-CoV-2 are reverse tran-
scription – quantitative polymerase chain reaction (RT-qPCR) 
assays. However, although a successful RT-qPCR amplification 
confirms an infection, the peak viral load is short lived and often 
occurs prior to or in the initial days after symptom onset and 
therefore the timing of the test is crucial2,3.
Patients tested after several days of illness may already have 
decreasing viral loads and negative RT-qPCR results and other 
markers of infection, such as immunoglobulins (Ig) could play 
an adjunct role in diagnosis, particularly in cases presenting 
≥10 days from onset of symptoms4. SARS-CoV-2 IgG and IgM 
can be detected in over 90% and 95% of hospitalised patients 
with confirmed infections respectively, with Ig presenting with 
simultaneous or sequential conversion5,6. Immunoglobulins are 
usually well established after 21 days of infection, but levels 
can be detectable at earlier timepoints7,8.
Global mobilisation in response to the pandemic resulted in the 
rapid development of lateral flow immunoassays (LFAs) for 
SARS-CoV-2. These assays can detect IgG, IgM, and occasion-
ally IgA antibodies, are relatively simple to use and generate 
results in 10–15 minutes, making them appropriate for the point 
of care. LFAs identify individuals who have formerly experienced 
infections (with or without symptoms), to document the preva-
lence of infection in the population. Moreover, LFAs could also 
complement the information generated by RT-qPCR for the 
diagnosis of patients with presumptive COVID-19, detecting an 
early rise of antibodies at the time that viral loads have become 
undetectable.
Most LFAs are evaluated in-house by the manufacturer. 
However, the WHO recommends these evaluations should be 
complemented by independent evaluations of diagnostic accu-
racy. Here, we report an evaluation of ten SARS-COV-2 LFAs in a 
cohort of patients with RT-qPCR confirmed SARS-CoV-2 




Research samples were provided with written consent. The 
study was based on samples collected for the International 
Severe Acute Respiratory and Emerging Infection Consortium 
(ISARIC) - Clinical Characterisation Consortium UK study. 
ISARIC CCP-UK is a prospective study based in 309 hospitals 
in England, Scotland, and Wales. The protocols, case report 
forms and details of its Independent Data and Material Access 
Committee are available online. Ethical approval for ISARIC 
CCP-UK was given by the South Central - Oxford C Research 
Ethics Committee in England (Ref 13/SC/0149), the Scotland 
A Research Ethics Committee (Ref 20/SS/0028), and the WHO 
Ethics Review Committee (RPC571 and RPC572, 25th April 
2013). The study protocol is available at http://isaric4c.net/pro-
tocols; study registry https://www.isrctn.com/ISRCTN66726260 
and at the ISARIC4C website (https://isaric4c.net/).
Participants
Forty-five participants with RT-qPCR-confirmed SARS-CoV-2 
infections admitted to National Health Service (NHS) hospi-
tals in the UK, were recruited through the ISARIC4C study. RT-
qPCRs were run by UK National Health Service (NHS) accredited 
laboratories. Patient sera were collected ≥4 days post-symp-
tom onset and one patient provided samples at two time points. 
Serum samples from a further 50 patients with influenza A 
(N=20), tuberculosis (N=5), documented previous flavivirus 
exposure through vaccination or infection (N=21) or healthy sera 
(N=4) that had been collected pre-pandemic were included as 
controls.
IgG enzyme-linked immunosorbent assay (ELISA)
All samples were screened by ELISA for the detection of 
anti-SARS-CoV-2 IgG (Omega Diagnostics, Alva, UK), as per the 
manufacturer’s instructions.
LFAs evaluated
All LFAs were evaluated using patient sera and compared to 
ELISA results. The LFAs included IgG/IgM RDT 1 (ASBT 
Holdings Ltd, Norfolk, UK), IgG/IgM RDT 2 (ASBT Hold-
ings Ltd, Norfolk, UK), COVID-19 Total Ab Device (Fortress 
Diagnostics, Antrim, UK), Rapid COVID-19 IgG/IgM Antibody 
Test (Suzhou Herui BioMed Co., Ltd, China), NADAL 
COVID-19 IgG/IgM rapid test (Nal von Minden, Moers, 
Germany), qSARS-CoV-2 IgG/IgM Rapid Test (Cellex, Durham, 
NC, USA), COVID-19 IgG/IgM Rapid Test (Nantong Egens 
Biotechnology, Nantong, China), NG-Test IgG-IgM COVID-
19 (NG Biotech, Guipry, France), Generation one RDT proto-
type (Mologic, Bedfordshire, UK), and Triple Antibody RDT 
(Mologic, Bedfordshire, UK). All tests detect anti-SARS-CoV-
2 IgG and IgM, except the Mologic LFAs which additionally 
detect anti-SARS-CoV-2 IgA. Serum samples for the evaluation 
had been stored at -80°C and were thawed to room temperature 
before use. LFAs were run at room temperature according to 
the manufacturer’s instructions, as summarised in Table 1. In 
brief, 5–10µl serum were added to the LFA well, followed by 
70–100µl of the proprietary test diluent in the same or a sepa-
rate buffer well. Test lines were scored as positive or negative by 
two independent readers at the specified reading time. The 
readers were blinded to each other’s results and discrepant scores 
were resolved by a third reader.
Statistical analysis
Data analysis was carried out in Microsoft Excel (version 2012). 
Sensitivity was calculated as the proportion of positive tests in 
convalescent sera of patients with RT-qPCR confirmed infec-
tions. Specificity was calculated as the proportion of negative tests 
among SARS-CoV-2 negative controls collected pre-pandemic. 
Further calculations of sensitivity and specificity were made 
when using the IgG ELISA as the reference standard. The levels of 
agreement were calculated using Cohen’s Kappa statistic9.
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Results
The 45 participants with confirmed SARS-CoV-2 infections 
had a median age of 58 years (IQR: 19) and 25 (56%) were male. 
Sensitivity of the LFAs ranged from 87% to 96%, with IgG rang-
ing from 83% to 94% and IgM between 24% and 96%. Specificity 
ranged from 92% to 100% for both IgG and IgM (Table 2). 
Differences in sensitivity and specificity across the tests were 
not statistically different. Sensitivity of the LFAs up to 3 weeks 
post-symptom onset ranged from 85% to 91% and from 83% 
to 100% after 3 weeks post-symptom onset. All tests except 
Generation one RDT prototype (Mologic, Bedfordshire, UK) 
recorded higher sensitivity over 3 weeks post-symptom onset 
(Extended data: Table S110).
Forty-two (91%) of the 45 participants with qPCR confirmed 
SARS-CoV-2 infections were IgG ELISA positive and 44 (88%) 
of the 50 controls were IgG ELISA negative. Using ELISA as 
the reference, LFA IgG sensitivity ranged from 91% [95% CI: 
77-97%] to 100% [95% CI: 92-100%] and specificity from 
93% [95% CI: 81-99%] to 100% [95% CI: 92-100%] (Extended 
data: Table S210). Differences across the tests were not statisti-
cally different. The percentage agreement between LFAs and 
ELISA ranged from 90% to 93%, as shown in Table 3. The greatest 
agreement between ELISA and a LFA was seen with the IgG/
IgM RDT 1 (ASBT Holdings Ltd), COVID-19 Total Ab Device 
(Fortress Diagnostics) and Rapid COVID-19 IgG/IgM Anti-
body Test (Suzhou Herui BioMed Co., Ltd) (kappa=0.854 for all 
three, corresponding to very good agreement).
Discussion
LFAs are potential tools for disease surveillance and the 
assessment of presence of antibodies to infection, which are rapid 
and easily conducted. In this study, we evaluated ten LFAs using 
sera from RT-qPCR confirmed SARS-CoV-2 infections and sera 
collected pre-pandemic. Although differences between tests were 
not statistically significant, the Fortress Total Ab Device had the 
highest overall sensitivity when compared to RT-qPCR. Across 
all tests, IgM had the widest sensitivity range (from 26% to 
96%) while IgG LFAs had similar ranges between 83% and 94%. 
Specificity was high across all assays and four out of the ten LFAs 
had specificity ≥ 98%. The IgG ELISA’s sensitivity and specifi-
city (Omega, UK) are 95% (≥7 days) and 97% (≥10 days) post- 
diagnosis, respectively11 and thus, as expected, the sensitivity and 
specificity of the LFAs was higher when ELISA was considered 
the reference standard. All LFAs had very high agreement with 
IgG ELISA. These data suggest LFAs can provide valuable 
data that is highly correlated to ELISAs, with an acknowledged 
small loss in sensitivity. LFAs have the advantage of being 
rapid and simple to run with no requirement for a laboratory or 
trained operators. This makes them highly suitable for low 
resource settings, self-testing, surveillance of the prevalence of 
infection or when rapid screening is required.
LFAs should have high specificity, especially in settings where 
infection rates are low, to avoid high numbers of false positives12. 
COVID-19 clinical presentation may be indistinguishable from 
other respiratory illnesses and LFAs could complement the 
information generated by RT-qPCR assays, with the tests 
combined identifying a larger number of individuals with 
current and previous SARS-CoV-2 infections. Moreover, with 
seasonal influenza likely coinciding with high COVID-19 
incidence, these assays could play a significant role to differ-
entiate SARS-CoV-2 from other viral infections and facilitate 
more targeted strategies for the management and quarantining of 
symptomatic patients.









IgG/IgM RDT 1 (ASBT Holdings Ltd) 10 80µl 10
IgG/IgM RDT 2 (ASBT Holdings Ltd) 10 100µl 10
COVID-19 Total Ab Device (Fortress Diagnostics) 5 2 drops 10
Rapid COVID-19 IgG/IgM Antibody Test (Suzhou Herui BioMed 
Co., Ltd, China)
10 70µl 10
NADAL® COVID-19 IgG/IgM rapid test (Nal von Minden) 10 2 drops 10
qSARS-CoV-2 IgG/IgM Rapid Test (Cellex) 10 2 drops 15–20
Covid-19 IgG/IgM Rapid Test (Nantong Egens Biotechnology) 10 2 drops 10
NG-Test® IgG-IgM COVID-19 (NG Biotech) 10 2 drops 15
Generation one RDT prototype (Mologic) 5 80µl 10
Triple Antibody RDT (Mologic) 5 80ul 10
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Table 2. Sensitivity and specificity of the LFAs. Sera from RT-qPCR-positive patients and a control panel of influenza A (N=20), TB 










IgG/IgM RDT 1 (ASBT Holdings Ltd) G + M 43 50 94 [82- 99] 100 [93-100]
G 43 50 94 [82-99] 100 [93-100]
M 17 50 37 [23- 53] 100 [93-100]
IgG/IgM RDT 2 (ASBT Holdings Ltd) G + M 43 47 94 [82-99] 94 [84-99]
G 41 50 89 [76- 96] 100 [93-100]
M 43 47 94 [82-99] 94 [84-99]
COVID-19 Total Ab Device (Fortress 
Diagnostics)
G + M 44 48 96 [85-100] 96 [86-100]
G 43 50 94 [82-99] 100 [93-100]
M 44 48 96 [85-100] 96 [86-100]
Rapid COVID-19 IgG/IgM Antibody Test 
(Suzhou Herui BioMed Co., Ltd, China)
G + M 42 49 91 [79-98] 98 [89-100]
G 42 49 91 [79- 98] 98 [89-100]
M 12 50 26 [14- 41] 100 [93-100]
NADAL® COVID-19 IgG/IgM rapid test 
(Nal von Minden)
G + M 43 48 94 [82-99] 96 [86-100]
G 40 50 87 [74-95] 100 [93-100]
M 43 48 94 [82-99] 96 [86-100]
qSARS-CoV-2 IgG/IgM Rapid Test (Cellex) G + M 43 49 94 [82-99] 98 [89-100]
G 43 49 94 [82-99] 98 [89-100]
M 11 50 24 [13-39] 100 [93- 100]
Covid-19 IgG/IgM Rapid Test (Nantong 
Egens Biotechnology)
G + M 43 46 94 [82-99] 92 [81-98]
G 43 46 94 [82- 99] 92 [81-98]
M 41 46 89 [76- 96] 92 [81-98]
NG-Test® IgG-IgM COVID-19 (NG 
Biotech)
G + M 41 47 89 [76-96] 94 [84-99]
G 41 50 89 [76- 96] 100 [93-100]
M 41 47 89 [76-96] 94 [84- 99]
Generation one RDT prototype 
(Mologic)
A + G + M 40 87 [74-95] 100 [93-100]
A 16 50 35 [21- 50] 100 [93-100]
G 24 50 83 [69 -92] 100 [93-100]
M 38 50 52 [37- 67] 100 [93-100]
Triple Antibody RDT (Mologic) A + G + M 42 48 94 [82-99] 96 [86-100]
A 35 50 78 [63-89] 100 [93-100]
G 28 48 93 [82-99] 96 [86-100]
M 42 48 62 [47-76] 96 [86-100]
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We acknowledge this validation has several limitations, as it 
included a small sample size, without enough power to find 
small differences in the performance of the assays, and there-
fore our findings can only be shown to be indicative of the likely 
findings of appropriately powered evaluations. All SARS-CoV-2 
positive samples were obtained from hospitalised patients as 
a marker of severe COVID-19 who may be expected to have 
high levels of antibodies, and our findings need to be replicated 
in asymptomatic individuals and in patients presenting with 
mild symptoms and in community settings. Furthermore, all 
testing was run under laboratory conditions by laboratory staff 
and the results may vary when conducted at the point of need 
and self-testing by untrained individuals. Finally, we were 
constrained to use serum, and further evaluations are needed 
to evaluate their performance on whole venous or capillary blood. 
Test performance on capillary blood, including a comparison 
of self-testing and laboratory testing, would inform the potential 
for use of less invasive sample collection methods.
Validation of test performance in people with presumptive 
SARS-COV-2 infection who are asymptomatic or are experienc-
ing mild infection is of particular interest as reports indicate a 
large proportion of individuals testing positive by RT-PCR have no 
symptoms on the day of sampling, a week prior and a week 
after a positive result13. LFAs ease of use and their fast time to 
results lends them to self-testing outside a clinical or laboratory 
environment. However, validation of test performance under these 
more challenging and less controlled environments is needed. 
Further evaluations of LFAs should include other coronaviruses 
and respiratory illnesses with overlapping signs and symptoms 
of COVID-19, including other causes of pneumonia, upper and 
lower respiratory infection, rhinoviruses, respiratory syncytial 
virus and influenza.
The impartial evaluation of LFAs, as recommended by the 
WHO, can confirm the evaluations of the developer’s validation 
data, and inform best-use settings. LFAs are a valuable tool which 
Table 3. Agreement and Cohen’s kappa of LFAs and ELISA IgG.
LFA ELISA Agreement (%) and Kappa 
[95% CI]
Positive Negative
IgG/IgM RDT 1 (ASBT Holdings Ltd) Positive 42 1
93% and 0.854 [0.751 to 0.958]
Negative 6 47
IgG/IgM RDT 2 (ASBT Holdings Ltd) Positive 41 0
93% and 0.854 [0.751 to 0.958]
Negative 7 48
COVID-19 Total Ab Device (Fortress 
Diagnostics)
Positive 39 1
90% and 0.792 [0.671 to 0.912]
Negative 9 47
Rapid COVID-19 IgG/IgM Antibody Test (Suzhou 
Herui BioMed Co., Ltd, China)
Positive 42 1
93% and 0.854 [0.751 to 0.958]
Negative 6 47
NADAL® COVID-19 IgG/IgM rapid test (Nal von 
Minden)
Positive 39 1
90% and 0.792 [0.671 to 0.912]
Negative 9 47
qSARS-CoV-2 IgG/IgM Rapid Test (Cellex) Positive 42 2
92% and 0.833 [0.723 to 0.944]
Negative 6 46
Covid-19 IgG/IgM Rapid Test (Nantong Egens 
Biotechnology)
Positive 42 4
80% and 0.792 [0.670 to 0.914]
Negative 6 44
NG-Test® IgG-IgM COVID-19 (NG Biotech) Positive 41 1
91% and 0.813 [0.698 to 0.928]
Negative 8 46
Generation one RDT prototype (Mologic) Positive 38 0
90% and 0.792 [0.672 to 0.911]
Negative 10 48
Triple Antibody RDT (Mologic) Positive 42 2
92% and 0.832 [0.721 to 0.943]
Negative 6 45
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could be applied at the point of need in conjunction with other 
assays to provide a more holistic diagnosis and to monitor the 
prevalence of infection. 
Data availability
Underlying data
Dryad: Comparative evaluation of ten lateral flow immunoassays 
to detect SARS-CoV-2 antibodies, doi.org/10.5061/dryad.
brv15dv8h10.
Extended data
Dryad: Comparative evaluation of ten lateral flow immunoassays 
to detect SARS-CoV-2 antibodies, doi.org/10.5061/dryad.
brv15dv8h10.
This project contains the following extended data:
     -      Table S1. Sensitivity of LFAs in RT-qPCR-positive 
samples ≤21 days (N=33) and >21 days post-symptom 
onset (N=12).
     -      Table S2. Sensitivity and specificity of the LFAs in 
comparison to IgG ELISA. Anti-SARS-CoV-2 ELISA-
IgG positive (N=42) and anti-SARS-CoV-2 ELISA-IgG 
negative samples (influenza A, N=18, TB, N=3, flavivirus 
exposure, N=21, and healthy controls, N=4).
Data are available under the terms of the Creative Commons 
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